PCR Journal Club

In the overall population (n = 2,114), there was a significant interaction between the effect of randomisation to OCT guidance vs angiography guidance in lesions with moderate/severe calcification (n = 1,082) vs no/mild calcification (n = 1,032) on the 2-year rate of TVF (Pinteraction = 0.01).

This exploratory analysis from the MASTER DAPT trial evaluates the effect of abbreviated versus prolonged DAPT on total ischaemic and bleeding events in high-bleeding-risk patients from the MASTER DAPT trial.

This study demonstrates that OCT-defined TCFA is a superior prognostic marker compared to μQFR for assessing NCLs in AMI patients.

The authors hypothesized that enriching invasive coronary angiography (ICA) with an advanced invasive diagnosis (AID) strategy would increase the diagnostic yield of obstructive and non-obstructive coronary artery disease (INOCA).

This registry-based observational study demonstrated that, in patients with STEMI and LTB, TA failure was associated with reduced myocardial perfusion and increased all-cause and cardiovascular mortality.

The current subanalysis of the BioVasc trial offers valuable insights into the long-term effects of ICR versus SCR strategies in STEMI patients with MVD. The findings support current guidelines on the necessity of revascularizing non-culprit lesions.

The rationale for this study was to provide direct evidence of colchicine's effects on plaque stabilization, particularly by assessing changes in plaque characteristics using optical coherence tomography (OCT).

This trial found that, in ACS patients undergoing PCI, DP-DES and BP-DES had similar patient-oriented outcomes at three years, but BP-DES had higher device-oriented composite outcomes, mainly due to increased TLR risk.

This pre-specified substudy of CompareCrush aimed to examine if patients with a large myocardial infarction benefit from prehospital crushed prasugrel.

This study sought to compare outcomes between patients presenting with STEMI before and after the recent ESC guidelines for the management of ACS recommend against pre-treatment with P2Y12 inhibitors in STEMI patients.